Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Olaparib (Primary) ; Temozolomide (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Oct 2017 Planned End Date changed from 1 Apr 2022 to 1 Aug 2022.
- 19 Oct 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2020.
- 19 Oct 2017 Status changed from active, no longer recruiting to recruiting.